IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I

$$R_1$$
 R_2
 R_1
 R_2
 R_3
 R_4
 R_4

wherein

- R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₆, CONR₇R₈, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or
 - phenyl optionally substituted with one to three halogen, hydroxy, C_1 - C_6 haloalkyl, C_1 - C_4 alkoxy, CO_2R_9 , $NR_{10}R_{11}$ or CN groups;
- R₃ is H, C₁-C₆alkyl optionally substituted with a phenyl, naphthyl or <u>C₅-C₁₀</u> heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N, O or S group each group optionally substituted with one to three C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or NR₁₃R₁₄ groups,
 - phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR₁₅R₁₆, SO₂NR₁₅R₁₆, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 - naphthyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N,</u>

 O or S optionally containing one double bond and optionally substituted with

one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO_2R_{17} or $NR_{18}R_{19}$ groups, or

- C₅-C₁₀ heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N,
 O or S optionally substituted with one to three halogen, NO₂, CN, C₁C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;
- R₄ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁,R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or</u>

R₅ is H, C₁-C₃alkyl or haloalkyl;

R₆, R₉, R₁₂, R₁₇, R₂₀, R₂₆ and R₂₇ are each independently H or a C₁-C₆alkyl, C₃-C₇ cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring system containing 1, 2 or 3 heteroatoms selected from N, O or S</u> group each optionally substituted;</u>

n is 0 or an integer of 1 or 2;

- R₇, R₈, R₁₀, R₁₁, R₁₃, R₁₄, R₁₈, R₁₉, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring</u> system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring</u> system containing 1, 2 or 3 heteroatoms selected from N, O or S group each optionally substituted or each of R₇ and R₈ or R₁₀ and R₁₁ or R₁₃ and R₁₄ or R₁₈ and R₁₉ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
- R₁₅ and R₁₆ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two CN, OR₅, NR₁₃R₁₄, CO₂R₁₇ or C₃-C₇cycloalkyl group;

phenyl optionally substituted with one or two halogen, OR₅, CN, NR₁₃R₁₄, CO₂R₁₇, COR₂₇, an optionally substituted C₁-C₈alkyl group or an optionally substituted C₂-C₆alkenyl group;

benzyl optionally substituted with one or two halogen, OR_5 , COR_{27} or a C_1 - C_6 alkyl group optionally substituted with one OR_5 or pyridinyl optionally substituted with one or two halogen, OR_5 , $NR_{13}R_{14}$ or CO_2R_{17} groups or

R₁₅ and R₁₆ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

- 2. (Original) The compound according to claim 1 wherein R₃ is an optionally substituted phenyl or heteroaryl group.
 - 3. (Original) The compound according to claim 1 wherein R_1 and R_2 are H.
- 4. (Original) The compound according to claim 1 wherein R_4 is a C_5 - C_7 cycloheteroalkyl, heteroaryl or phenyl group each optionally substituted with one or two halogen, CN, NO₂, CF₃, methoxy, carboxy or SOR₂₆ groups.
 - 5. (Original) The compound according to claim 2 wherein R₁ and R₂ are H.
- 6. (Original) The compound according to claim 2 wherein R_4 is a thienyl, pyridyl or phenyl group, each optionally substituted with one or two halogen, CN, NO_2 , CF_3 , methoxy, carboxy or $SOCH_3$ groups.
- 7. (Original) The compound according to claim 3 wherein R_3 is a phenyl group substituted with one or two halogen, $CONR_{15}R_{16}$ or $SO_2NR_{15}R_{16}$ groups.
- 8. (Original) The compound according to claim 7 wherein R₄ is a phenyl group substituted with one NO₂ or CF₃ group.
- 9. (Currently Amended) The compound according to claim 1 selected from the group consisting of:
- 2-(4-chlorophenyl)-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazolo-
 - [3,4-d]thieno[2,3-b]pyridin-3-one;
- 2-(4-fluorophenyl)-4-[3-(trifluoromethyl)phenyl]-1,2-dihydro-3H-pyrazolo-[3,4-d]thieno[2,3-b]pyridin-3-one;

N-(3,4-dihydroxybenzyl)-3-{3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrazolo[3,4-d]thieno[2,3-b]pyridin-2(1H)-yl}benzamide;

- N-[3-(1-hydroxyethyl)phenyl]-4-{3-oxo-4-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrazolo[3,4-d]thieno[2,3-b]pyridin-2(1H)-yl}benzamide;
- ({[4-(6-methyl-3-oxo-4-[3-(trifluoromethyl)phenyl]-dihydropyrazolo-

[3,4-d]thieno[2,3-b]pyridin-2(1H)-yl)phenyl]sulfonyl}amino)acetic acid;

the stereoisomers thereof; or and the pharmaceutically acceptable salts thereof.

10. (Currently Amended) A method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which comprises providing a patient in need thereof an immunotherapeutically effective amount of a compound of formula

$$R_1$$
 R_2
 R_1
 R_3
 R_4
 R_4

wherein

R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₆, CONR₇R₈, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or

phenyl optionally substituted with one to three halogen, hydroxy, C_1 - C_6 haloalkyl, C_1 - C_4 alkoxy, CO_2R_9 , $NR_{10}R_{11}$ or CN groups;

R₃ is H, C₁-C₆alkyl optionally substituted with a phenyl, naphthyl or <u>C₅-C₁₀</u> heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N, O or S group each group optionally substituted with one to three C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or NR₁₃R₁₄ groups,

phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR₁₅R₁₆, SO₂NR₁₅R₁₆, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,

naphthyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO_2R_{17} , $NR_{18}R_{19}$ or $CH_2CO_2R_{20}$ groups,

C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups, or</u>

- C₅-C₁₀ heteroaryl <u>ring system containing 1, 2 or 3 heteroatoms selected from N,</u>
 O or S optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;
- R₄ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups,
 - cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and</u> optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁,R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or
 - C₅-C₁₀ heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N,
 O or S optionally substituted with one or more halogen, NO₂, CN, hydroxy,
 C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy,
 benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;

 R_5 is H, C_1 - C_3 alkyl or haloalkyl;

R₆, R₉, R₁₂, R₁₇, R₂₀, R₂₆ and R₂₇ are each independently H or a C₁-C₆alkyl, C₃-C₇ cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring system containing 1</u> or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring system containing 1, 2 or 3 heteroatoms selected from N, O or S</u> group each optionally substituted;

n is 0 or an integer of 1 or 2;

- R₇, R₈, R₁₀, R₁₁, R₁₃, R₁₄, R₁₈, R₁₉, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring</u> system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring</u> system containing 1, 2 or 3 heteroatoms selected from N, O or S group each optionally substituted or each of R₇ and R₈ or R₁₀ and R₁₁ or R₁₃ and R₁₄ or R₁₈ and R₁₉ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
- R₁₅ and R₁₆ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two CN, OR₅,

NR₁₃R₁₄, CO₂R₁₇ or C₃-C₇cycloalkyl group;

phenyl optionally substituted with one or two halogen, OR₅, CN, NR₁₃R₁₄, CO₂R₁₇, COR₂₇, an optionally substituted C₁-C₈alkyl group or an optionally substituted C₂-C₆alkenyl group;

benzyl optionally substituted with one or two halogen, OR_5 , COR_{27} or a C_1 - C_6 alkyl group optionally substituted with one OR_5 or pyridinyl optionally substituted with one or two halogen, OR_5 , $NR_{13}R_{14}$ or CO_2R_{17} groups or

R₁₅ and R₁₆ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

- 11. (Original) The method according to claim 10 wherein said disorder is transplant rejection.
- 12. (Original) The method according to claim 10 wherein said disorder is an autoimmune disease.
- 13. (Original) The method according to claim 10 wherein said disorder is graft vs. host disease.
- 14. (Original) The method according to claim 12 wherein said disease is multiple sclerosis or rheumatoid arthritis.
- 15. (Currently Amended) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I

$$R_1$$
 R_2
 R_3
 R_1
 R_3
 R_4

(I)

wherein

R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₆, CONR₇R₈, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or

- phenyl optionally substituted with one to three halogen, hydroxy, C_1 - C_6 haloalkyl, C_1 - C_4 alkoxy, CO_2R_9 , $NR_{10}R_{11}$ or CN groups;
- R₃ is H, C₁-C₆alkyl optionally substituted with a phenyl, naphthyl or <u>C₅-C₁₀</u> heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N, O or S group each group optionally substituted with one to three C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or NR₁₃R₁₄ groups,
 - phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR₁₅R₁₆, SO₂NR₁₅R₁₆, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 - naphthyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups, or</u>
 - C₅-C₁₀ heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N,
 O or S optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;
- R₄ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁,R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or</u>
 - C₅-C₁₀ heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N,

 O or S optionally substituted with one or more halogen, NO₂, CN, hydroxy,

 C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy,

 benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups;
 - R_5 is H, C_1 - C_3 alkyl or haloalkyl;
 - R_6 , R_9 , R_{12} , R_{17} , R_{20} , R_{26} and R_{27} are each independently H or a C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_1 - C_6 haloalkyl, phenyl, C_5 - C_7 cycloheteroalkyl <u>ring system containing 1</u>

or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N, O or S group each optionally substituted;

n is 0 or an integer of 1 or 2;

- R₇, R₈, R₁₀, R₁₁, R₁₃, R₁₄, R₁₈, R₁₉, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring</u> system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring</u> system containing 1, 2 or 3 heteroatoms selected from N, O or S group each optionally substituted or each of R₇ and R₈ or R₁₀ and R₁₁ or R₁₃ and R₁₄ or R₁₈ and R₁₉ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
- R₁₅ and R₁₆ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two CN, OR₅,

NR₁₃R₁₄, CO₂R₁₇ or C₃-C₇cycloalkyl group;

- phenyl optionally substituted with one or two halogen, OR₅, CN, NR₁₃R₁₄, CO₂R₁₇, COR₂₇, an optionally substituted C₁-C₈alkyl group or an optionally substituted C₂-C₆alkenyl group;
- benzyl optionally substituted with one or two halogen, OR_5 , COR_{27} or a C_1 - C_6 alkyl group optionally substituted with one OR_5 or pyridinyl optionally substituted with one or two halogen, OR_5 , $NR_{13}R_{14}$ or CO_2R_{17} groups or
- R₁₅ and R₁₆ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or

the stereoisomers thereof or the pharmaceutically acceptable salts thereof.

- 16. (Original) The composition according to claim 15 having a formula I compound wherein R_3 is an optionally substituted phenyl, thienyl or pyridyl group.
- 17. (Original) The composition according to claim 16 having a formula I compound wherein R_1 and R_2 are H.
- 18. (Original) The composition according to claim 17 having a formula I compound wherein R_4 is a thienyl, pyridyl or phenyl group each optionally substituted with one or two halogen, CN, NO₂, CF₃, methoxy, carboxy or SOCH₃ groups.

19. (Original) The composition according to claim 18 having a formula I compound wherein R_3 is a phenyl group substituted with one or two halogen, CONR₁₅R₁₆ or SO₂NR₁₅R₁₆ groups.

20. (Currently Amended) A process for the preparation of a compound of formula

$$R_1$$
 R_2
 R_1
 R_2
 R_3
 R_4

(I)

wherein

R₁ and R₂ are each independently H, C₁-C₁₀alkyl optionally substituted with one or more halogen, hydroxy, C₁-C₄alkoxy, CO₂R₆, CONR₇R₈, C₃-C₇cycloalkyl or optionally substituted phenyl groups, or

phenyl optionally substituted with one to three halogen, hydroxy, C_1 - C_6 haloalkyl, C_1 - C_4 alkoxy, CO_2R_9 , $NR_{10}R_{11}$ or CN groups;

- R₃ is H, C₁-C₆alkyl optionally substituted with a phenyl, naphthyl or <u>C₅-C₁₀</u> heteroaryl ring system containing 1, 2 or 3 heteroatoms selected from N, O or S group each group optionally substituted with one to three C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, hydroxy, CHO, NO₂, CN, CO₂R₁₂ or NR₁₃R₁₄ groups,
 - phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CONR₁₅R₁₆, SO₂NR₁₅R₁₆, CO₂R₁₇, NR₁₈R₁₉ or CH₂CO₂R₂₀ groups,
 - naphthyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, CO_2R_{17} , $NR_{18}R_{19}$ or $CH_2CO_2R_{20}$ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N,</u>
 O or S optionally containing one double bond and optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁7 or NR₁8R₁9 groups, or

C₅-C₁₀ heteroaryl <u>ring system containing 1, 2 or 3 heteroatoms selected from N, O or S</u> optionally substituted with one to three halogen, NO₂, CN, C₁-C₆alkyl, C₁-C₆haloalkyl, C₁-C₄alkoxy, CO₂R₁₇ or NR₁₈R₁₉ groups;

- R₄ is phenyl optionally substituted with one to three halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups,
 - C₅-C₇cycloheteroalkyl <u>ring system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond and optionally substituted with one or more halogen, NO₂, CN, hydroxy, C₁-C₆alkyl, C₁-C₆alkylthio, C₁-C₆haloalkyl, C₁-C₆alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SO_nR₂₆, SO₂NR₂₁,R₂₂, CO₂R₂₃ or NR₂₄R₂₅ groups, or</u>

R₅ is H, C₁-C₃alkyl or haloalkyl;

R₆, R₉, R₁₂, R₁₇, R₂₀, R₂₆ and R₂₇ are each independently H or a C₁-C₆alkyl, C₃-C₇ cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring system containing 1</u> or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring system containing 1, 2 or 3 heteroatoms selected from N, O or S</u> group each optionally substituted;

n is 0 or an integer of 1 or 2;

- R₇, R₈, R₁₀, R₁₁, R₁₃, R₁₄, R₁₈, R₁₉, R₂₁, R₂₂, R₂₄ and R₂₅ are each independently H or a C₁-C₆alkyl, C₃-C₇cycloalkyl, C₁-C₆haloalkyl, phenyl, C₅-C₇cycloheteroalkyl <u>ring</u> system containing 1 or 2 heteroatoms selected from N, O or S optionally containing one double bond or C₅-C₁₀ heteroaryl <u>ring</u> system containing 1, 2 or 3 heteroatoms selected from N, O or S group each optionally substituted or each of R₇ and R₈ or R₁₀ and R₁₁ or R₁₃ and R₁₄ or R₁₈ and R₁₉ or R₂₁ and R₂₂ or R₂₄ and R₂₅ may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; and
- R₁₅ and R₁₆ are each independently H, NH₂, CH₂CH₂OCH₂CH₂OCH₂CH₂NH₂ or a C₁-C₆alkyl group optionally substituted with one or two CN, OR₅,

NR₁₃R₁₄, CO₂R₁₇ or C₃-C₇cycloalkyl group;

phenyl optionally substituted with one or two halogen, OR₅, CN, NR₁₃R₁₄, CO₂R₁₇, COR₂₇, an optionally substituted C₁-C₈alkyl group or an optionally substituted C₂-C₆alkenyl group;

benzyl optionally substituted with one or two halogen, OR₅, COR₂₇ or a

 C_1 - C_6 alkyl group optionally substituted with one OR $_5$ or pyridinyl optionally substituted with one or two halogen, OR $_5$, NR $_{13}$ R $_{14}$ or CO_2 R $_{17}$ groups or

R₁₅ and R₁₆ may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, N or S; or

which process comprises reacting a compound of formula VI

$$R_1$$
 $CO_2C_2H_2$
 (VI)

wherein R_1 , R_2 and R_4 are described hereinabove with a hydrazine, R_3NHNH_2 , to give a 3-hydrazinylthieno-[2,3-b]pyridine intermediate; and cyclizing said intermediate to give the desired compound of formula I.